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Abstract
Background: The Levels of Evidence Rating System is widely believed to categorize studies by quality, with Level
I studies representing the highest quality evidence. We aimed to determine the reporting quality of Randomised
Controlled Trials (RCTs) published in the most frequently cited general orthopaedic journals.
Methods: Two assessors identified orthopaedic journals that reported a level of evidence rating in their abstracts
from January 2003 to December 2004 by searching the instructions for authors of the highest impact general
orthopaedic journals. Based upon a priori eligibility criteria, two assessors hand searched all issues of the eligible
journal from 2003–2004 for RCTs. The assessors extracted the demographic information and the evidence rating
from each included RCT and scored the quality of reporting using the reporting quality assessment tool, which
was developed by the Cochrane Bone, Joint and Muscle Trauma Group. Scores were conducted in duplicate, and
we reached a consensus for any disagreements. We examined the correlation between the level of evidence rating
and the Cochrane reporting quality score.
Results: We found that only the Journal of Bone and Joint Surgery – American Volume (JBJS-A) used a level of
evidence rating from 2003 to 2004. We identified 938 publications in the JBJS-A from January 2003 to December
2004. Of these publications, 32 (3.4%) were RCTs that fit the inclusion criteria. The 32 RCTs included a total of
3543 patients, with sample sizes ranging from 17 to 514 patients. Despite being labelled as the highest level of
evidence (Level 1 and Level II evidence), these studies had low Cochrane reporting quality scores among individual
methodological safeguards. The Cochrane reporting quality scores did not differ significantly between Level I and
Level II studies. Correlations varied from 0.0 to 0.2 across the 12 items of the Cochrane reporting quality
assessment tool (p > 0.05). Among items closely corresponding to the Levels of Evidence Rating System criteria
assessors achieved substantial agreement (ICC = 0.80, 95%CI:0.60 to 0.90).
Conclusion: Our findings suggest that readers should not assume that 1) studies labelled as Level I have high
reporting quality and 2) Level I studies have better reporting quality than Level II studies. One should address
methodological safeguards individually.
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Background
The International Society of Medical Editors emphasises
the importance of effective reporting in medical literature
[1,2]. However, previous studies have identified poor
quality of reporting of study methodology in the ortho-
paedic literature [3,4].
Since January 2003, all clinical scientific articles published
in the American Volume of The Journal of Bone and Joint
Surgery (JBJS-A) have included a level of evidence rating
[5,6]. The Levels of Evidence Rating System is a tool that
classifies the quality and design of a study. Based on a
review of several existing evidence rating systems [5,6],
JBJS-A has designed a scheme that uses five hierarchical
levels for each of the four different study reporting types
(therapeutic studies, prognostic studies, diagnostic stud-
ies, and economic and decision analyses). According to
the Levels of Evidence Rating System hierarchy, ran-
domised controlled trials (RCTs) occupy the top positions
(Level I & Level II evidence) and expert opinion lies at the
bottom (Level V evidence). Previous research has sug-
gested that investigators with training in epidemiology
can achieve nearly perfect agreement when applying the
Levels of Evidence Rating System to a study [7]. This
research suggests reliability; however, the system's validity
remains debatable [7].
The Levels of Evidence Rating System causes readers to
infer that Level I evidence RCTs are of better methodolog-
ical quality than Level II evidence RCTs [8]. The Editorial
Board Members of the JBJS-A reported that the Levels of
Evidence Rating System would have important advantages
such as enabling the journal "to monitor and to periodi-
cally report trends in the quality of orthopaedic clinical
research" [5]. Furthermore, the editors wrote that "higher
levels of evidence should be more convincing to surgeons
attempting to resolve clinical dilemmas" [5].
The assessment of the true quality of published studies
remains challenging [9-11]. One can judge the true study
quality only if the reporting of the trial is done in a clear
and comprehensive manner. For example, in some pub-
lished articles within Internal Medicine literature, the
authors failed to report important methodological safe-
guards that were in fact used during the conduct of the
trial [12]. Therefore, high quality depends not only on the
nature of the work, but also on the completeness of the
reporting [2]. Most readers of medical literature will base
their assessment of study quality solely on the informa-
tion contained in the report of a trial, as they will not be
bothered to contact the author for additional information
[12].
The most developed criteria for guiding clinicians in their
assessment of study reporting quality have been proposed
for RCTs, since RCTs are a study design that yield the low-
est chance of bias [11,13]. The Consolidated Standards for
Reporting of Trials (CONSORT) statement was developed
to help authors present their trial in a structured and com-
plete manner. Assessors, on the other hand, use different
tools to assess the quality of a trial. The Cochrane Collab-
oration, which is the largest database of systematic
reviews (N = 4041, October 2005) and clinical trials (N =
454449, October 2005) in existence, has adopted one
commonly utilized rating system to guide assessors in
their assessment of study quality, as evaluated through the
information contained in the report [9,14].
Given the upcoming use of the Levels of Evidence Rating
System in orthopaedic literature, we aimed to evaluate the
reporting quality of RCTs published in the JBJS-A from
2003 to 2004 (Level I and Level II evidence ratings). We,
therefore, extracted the level of evidence rating as pub-
lished in each RCT and compared this rating with the
well-established Cochrane Bone, Joint and Muscle
Trauma Group's reporting quality assessment tool. We
chose the JBJS-A because it was the most frequently sited
general orthopaedic journal (ISI web of science), and the
only journal that used this Levels of Evidence Rating Sys-
tem in the eligible time period.
Our hypotheses were twofold: 1) Level I evidence studies
in a high impact general orthopaedic journal would not
necessarily have high quality reporting and 2) the report-
ing quality of RCTs would not differ among trials labelled
as Level I or Level II evidence.
Methods
Study design
We conducted a methodological study. We assessed the
level of evidence rating assigned to a series of RCTs with
the Cochrane reporting quality score.
Eligibility criteria
Two assessors (RWP, MB) identified orthopaedic journals
that reported a level of evidence rating in their abstracts
from January 2003 to December 2004 by searching the
instructions for authors of the highest impact general
orthopaedic journals (JBJS-A, JBJS-British Volume, Clini-
cal Orthopaedics and Related Research, and Acta Ortho-
paedica). Within the eligible journal, two assessors (RWP,
RK) hand searched all issues from 2003–2004. The eligi-
bility criteria were determined and set a priori. Eligible
studies included those reported as RCTs involving a ther-
apeutic intervention and using human subjects. We con-
ducted searches in duplicate, and the consensus of three
authors (RWP, RK, MB) resolved any disagreements.BMC Medical Research Methodology 2006, 6:44 http://www.biomedcentral.com/1471-2288/6/44
Page 3 of 8
(page number not for citation purposes)
Study demographic information
The relevant demographic information was extracted
from each eligible study by one investigator (RWP) and
rechecked for accuracy by a second investigator (PAAS).
The extracted data included (1) first author (surgeon, non-
surgeon, or epidemiologist), (2) cited statistical support
or methodological support by a department of clinical
epidemiology or public health, (3) year of publication,
(4) total sample size, (5) number of centres, (6) name of
intervention, (7)category of intervention (fracture treat-
ment, treatment of degenerative disease of the spine and
joints, drug trial, pain management, or other), (8) body
region (upper extremity, long bones of lower extremity,
spine, hip and knee, or foot and ankle, DVT, or other),(9)
financial support (yes or no), (10) direction of
results(positive [if the findings of the randomised trial
were significant]or negative [if they were not significant]),
and (11) trial reported according to the CONSORT state-
ment (yes or no).
Levels of evidence
One of the authors (RWP) extracted the level of evidence
from each abstract of the included RCTs. A second author
(INS) double-checked the evidence rating to ensure that it
was correctly extracted from the paper.
Quality of reporting assessment
Two authors (RWP, PAAS), blinded to study author and
institution, graded the reporting quality of the included
RCTs using the Cochrane reporting quality assessment
tool, which was devised by the Cochrane Bone, Joint and
Muscle Trauma Group, formally known as the Muscu-
loskeletal Injuries Group. This scoring scheme covers
aspects of internal and external validity for the assessment
of methodological quality [15]. We used this reporting
quality assessment tool as our reference standard due to
its widespread use [15] and association with the method-
ologically rigorous Cochrane reviews of RCTs [9,16,17].
The tool consists of twelve items important for the critical
appraisal of a RCT report. A coding manual was available
from the group's website [15]. The highest possible score
for each item was 2 and the lowest was 0. Additional file
1 contains the scoring system that we used to identify the
important aspects of reporting methodological quality
[see Additional file 1]. We followed therecommendation
found in the Cochrane Handbook which stated that at
least two authors assess information that involves subjec-
tive interpretation and information that is critical to the
interpretation of results (e.g., outcome data) [18].
Studies that randomly allocated patients (Item D), con-
cealed randomisation (Item A), blinded participants
(Items C, E, F) and documented study withdrawals (Item
B) were reported to reflect higher quality [19,20]. We
scored all reported methodological safeguards separately
for all identified RCTs. Different quality aspects can be
weighted differently and thresholds are arbitrary [10];
therefore, we did not summarize the scores in totals, but
reported the raw data.
Ensuring the accuracy of the quality rating
We used Intraclass Correlation Coefficients (ICC) to
measure the agreement between the assessors' assessment
of study reporting quality. We used Landis and Koch's sug-
gested criteria for the interpretation of the agreement: 0 to
0.2 represented slight agreement, 0.21 to 0.40 fair agree-
ment, 0.41 to 0.60 moderate agreement, and 0.61 to 0.80
substantial agreement. A value above 0.80 was considered
almost perfect agreement [21]. Regardless, if two assessors
disagreed even slightly, consensus was attempted after
carefully reading the article a second time in a consensus
meeting. In situations where discrepancies persisted
despite a consensus meeting, a third assessor was asked
for an opinion on the specific item to reach final consen-
sus. This method of quality assessment a final consensus
meeting has been commonly used in Cochrane reviews.
All assessors (RWP, PAAS, MB, and RK) were well trained
in quality assessments, were clinically active in orthopae-
dic surgery, had completed a Cochrane Review course,
and had co-authored in Cochrane systematic reviews of
RCTs.
Statistical analysis
Data was analysed using the SPSS statistical software pack-
age (version 11.2; SPSS, Chicago, Illinois). We summa-
rized all individual Cochrane reporting quality items with
mean scores, which we then compared with student t-
tests. We compared more than two means with single fac-
tor analysis of variance adjusted for post-hoc comparison
testing. We then compared the total scores (0–2) for each
item in the Cochrane reporting quality assessment tool
with the level of evidence rating as published in JBJS-A.
Prior to the analysis, we identified Cochrane Items A, C, E,
F, and L to be most similar to the description of the levels
of evidence. In a subgroup analysis, we compared the lev-
els of evidence as described in the instructions for authors
with the Cochrane reporting quality items that were
deemed similar (Table 1). We used the Spearman's corre-
lation (non-parametric test, non-normally distributed
data) to calculate the correlation between the JBJS-A level
of evidence rating and the total Cochrane reporting qual-
ity score, and the correlation between the JBJS-A level of
evidence rating and Items A, C, E, F, and L of the Cochrane
reporting quality score. For correlations, we categorized
the levels of evidence from 1 to 4 (1 = level 1A, 2 = level
1B, 3 = level 2-1, 4 = level2-2) with 1 representing the
highest level. We used p < 0.05 to represent statistical sig-
nificance. All tests of significance were two-tailed.BMC Medical Research Methodology 2006, 6:44 http://www.biomedcentral.com/1471-2288/6/44
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Sample size
Our study sample size included all RCTs published in the
JBJS-A from January 2003 to December 2004. We required
at least 30 eligible RCTs to provide sufficient correlation
data on the level of evidence ratings and the Cochrane
reporting quality scores (alpha = 0.05, Beta = 0.20, rhonull
= 0.2, rho = 0.7).
Results
Study demographic information
Of the four high impact orthopaedic journals, only JBJS-A
used the level of evidence rating from 2003 to 2004. We
identified 938 publications in the JBJS-A from January
2003 to December 2004. Of these publications, 32 (3.4%)
were RCTs that fit the eligibility criteria. Thirty (94%) of
the first authors were surgeons and 2 (6%) were non-sur-
geons. In 5 (16%) of the RCTs, at least one author had
cited training in biostatistics (MSc or PhD) or was affili-
ated with a department of statistics, public health, or clin-
ical epidemiology. The 32 RCTs included a total of 3543
patients, with sample sizes ranging from 17 to 514
patients. Six (19%) of the studies were performed in two
or more centres, 11 (34%) focused on interventions
related to the treatment of degenerative joint disease, 7
(22%) focused on fractures, and the remainder involved
problems affecting the upper extremity [5 (16%)], the
foot and ankle [6 (19%)], and the knee [9 (28%)]. Four
(13%) RCTs were reported according to the CONSORT
statement (Table 2). References to the included studies
can be found in Additional file 2 [see Additional file 2].
Levels of evidence
Of the 32 included RCTs, 29 were reported as Level I stud-
ies and 3 were reported as Level II studies. Level I studies
were further subgrouped into 22 Level-1A and 7 Level -1B
(RCT-no significant difference, but narrow confidence
intervals) studies. Level II studies were also subgrouped
into 1 Level II-1 and 2 level II-2 studies as extracted from
the included papers' abstract.
Limitations in quality of reporting (Hypothesis 1)
Only 12 (38%) of the 32 included RCTs clearly described
allocation concealment (Item A). Seven (22%) clearly
described an intention to treat analysis (Item B). Thirteen
(41%) clearly described the blinding of outcome assessors
(Item C). Twenty-three (72%) clearly described the com-
parability of the treatment and control group at entry
(Item D). Six (19%) of the 32 RCTs clearly described the
blinding of participants (Item E). Only 2 (6%) of the stud-
ies clearly described the blinding of treatment providers
(Item F). Seventeen (53%) clearly described identical care
programmes other than the trial options (Item G). Of the
32 RCTs, 25 (78%) adequately described the inclusion
and exclusion criteria (Item H). Of all the items, I and J
were described best in all 32 RCTs: 31 (97%) clearly
described the interventions and 31 (97%) clearly
described the outcome measures used. Twenty-two (69%)
clearly described a useful diagnostic test in the outcome
assessment (Item K). Only 10 (31%) described an appro-
priate duration of follow-up (Item L).Table 3 shows all
data for each RCT.
Among items closely corresponding to the Levels of Evi-
dence Rating System criteria (Items A, C, E, F, and L),
assessors achieved substantial agreement (ICC = 0.80,
95%CI:0.60 to 0.90). Across each of the 12 items, how-
ever, agreement varied (Range of ICC = 0 to 0.80). In all
cases, assessors achieved consensus, either alone or with a
third, intervening reviewer.
Correlation between Cochrane reporting quality scores 
and reported levels of evidence (Hypothesis 2)
We compared the mean score in each item of the
Cochrane reporting quality assessment tool separately
(Items A through L) with each level of evidence (Table 4).
Mean quality scores did not significantly differ across the
12 separate items of the Cochrane reporting quality
assessment tool (Table 4). Correlations varied from 0.0 to
0.2 across the 12 items of the Cochrane reporting quality
assessment tool (Table 4).
Discussion
Summary of key study findings
The results of our methodological study demonstrated
two key findings 1) Level I evidence studies revealed
important limitations in their quality of reporting and 2)
Table 1: Cochrane Items Closely Related to the Levels of Evidence
Levels of Evidence JBJS in instruction for Authors Cochrane Item
Level Description A B C D E F G H I J K L
I High-quality randomised controlled trial with statistically significant difference or no 
statistically significant difference but narrow confidence intervals
2X2x22x xxxx2
II Lesser-quality randomised controlled trial (e.g., <80% follow-up, no blinding, or 
improper randomisation)
0X0x00x xxxx0
Levels of Evidence compared with separate Cochrane items. 2 is maximal possible Cochrane score. 0 is minimal possible score. X is not described 
in instruction for authors.BMC Medical Research Methodology 2006, 6:44 http://www.biomedcentral.com/1471-2288/6/44
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non- significant difference in the quality of reporting
between studies labelled as Level I or Level II evidence.
Strengths and weaknesses
Our study is strengthened by the use of a well-described
and commonly used quality assessment tool from the
Cochrane Collaboration that identifies the relevant meth-
odological aspects of trials as reported and assesses these
aspects individually. Furthermore, all assessors (RWP,
PAAS, MB, RK) were well trained in quality assessments.
Our decision to conduct assessments in duplicate (and
triplicate when assessors disagreed) further strengthened
the rigor of our assessments [18]. The paucity of Level II
studies in our series limited inferences about the correla-
tion data with level of evidence ratings. Our finding that
the mean overall scores between Level I and Level II stud-
ies did not significantly differ was likely underpowered.
The sample size calculation was difficult since clinicians
have made arguments against calculating totals in quality
scores (see discussion below). However, to identify a dif-
ference in quality scores of 3.5 points, we required at least
12 Level II studies (80% study power, alpha = 0.05). The
more relevant comparison of the abridged quality scores
that reflect the level of evidence criteria suggested that we
would require at least 22 Level II studies. Given that only
3 Level II therapy studies have been published over the
two-year period, it may require a decade to gain this addi-
tional information from the JBJS-A unless the Levels of
Evidence Rating System is widely adopted by multiple
orthopaedic journals. Therefore, our findings represent
the current best estimate of association until more studies
become available for comparison. Our study does, how-
ever, have a sufficient number of RCTs to observe varia-
tion in the study reporting quality scores. Since 2005, the
JBJS-A has abandoned the uses of Level I and II subgroups;
therefore, the relevance of analysing differences between
Level Ia and Ib studies is limited. Our study described
RCTs in one journal dedicated to one surgical field.
Although this journal's scope is general orthopaedics, our
findings are not generalisable to other surgical fields and
journals.
Previous literature
A previous review of published studies in The Journal of
Bone and Joint Surgery 1988 through 2000 revealed a
similar proportion (3%) of randomised trials compared
with our current study (3.4%) [4]. The Cochrane Bone,
Joint and Muscle Trauma Group's reporting quality assess-
ment tool describes the following aspects of quality
assessment which have previously been shown to be
important in preventing bias [9]: allocation concealment,
blinding, generation of allocation sequence, similarity of
groups at baseline, description of outcomes, intention to
treat analysis, and losses to follow-up. Currently, no con-
sensus on the ideal checklist and scale for assessing meth-
odological quality exists [9]. The number and variety of
quality assessment scales that exist make it unclear as to
how to achieve the best assessment [10,11]. The Levels of
Evidence Rating System used by the JBJS-A can be quali-
fied as one of these quality assessment scales. Summary
scores (totals) should not be calculated, although it may
be tempting to do so. The use of thresholds skews the
direction of results and may lead to false conclusions in a
meta-analyses [10]. Furthermore, Juni et al. discouraged
the use of individual scales as absolute and objective
measures of trial quality and noted "relevant methodolog-
ical aspects should be identified, ideally a priori, and
assessed individually" [10,18]. For example, the same cri-
teria for blind assessment cannot be applied to drug and
surgical trials, since, in the latter group, treatments are
usually more difficult to conceal. Ideally, scales that are
used to measure the quality of reporting of surgical trials
should be tailored to the maximal possible quality, rather
than to a unique gold-standard quality [10]. Therefore,
the Cochrane Collaboration's handbook advises to
Table 2: Characteristics of the Thirty-two Trials
Characteristics No. of Studies (%)
Total No. of RCTs 32 (100%)
First author
Surgeon 31 (97%)
Nonsurgeon 1 (3%)
Epidemiology affiliation
Yes 3 (9%)
No 29 (91%)
Category of trial
Fracture treatment 7 (22%)
Treatment of degenerative disease 11 (34%)
Drug trial 4 (13%)
Pain management 0 (0%)
Other 10 (31%)
Region of body
Upper extremity 5 (16%)
Lower-extremity long bones 2 (6%)
Spine 2 (6%)
Hip 5 (16%)
Knee 9 (28%)
Foot and ankle 6 (19%)
Soft tissue 2 (6%)
DVT 1 (3%)
Number of centres
Single 26 (81%)
Multi 6 (19%)
Funding received
Yes 17 (53%)
No 15 (47%)
Direction of results
Positive 24 (75%)
Negative 8 (25%)
CONSORT
Yes 4 (13%)
No 28 (87%)BMC Medical Research Methodology 2006, 6:44 http://www.biomedcentral.com/1471-2288/6/44
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Table 3: Cochrane Bone, Joint and Muscle Injury Group scores for all 32 RCTs.
Study Level of 
Evidence
Cochrane Bone, Joint and Muscle Trauma Group reporting quality assessment score item (see below)
ABCDE F GHI J KL
1 I I - 2 00000 0 222121
2 I - 1 b11220 0 222222
3 I - 1 a 10222 0 122211
4 I - 1 a 11020 0 222211
5 I I - 2 21000 0 022222
6 I - 1 b20220 0 022221
7 I - 1 a 10020 0 222220
8 I - 1 a 12020 0 122222
9 I - 1 a 20020 0 112222
1 0I - 1 a 10020 0 212211
1 1I - 1 b10200 0 212211
1 2I - 1 a 12010 0 111222
1 3I - 1 a 20120 0 012211
1 4I - 1 a 01020 0 122221
1 5I - 1 a 21020 0 122221
1 6I - 1 a 11010 0 012221
1 7I - 1 b00000 0 022211
1 8I - 1 a 01200 0 222220
1 9I - 1 a 21220 0 222222
2 0I - 1 a 12022 0 222221
2 1I - 1 a 10220 0 222222
2 2I - 1 a 11000 0 222222
2 3I - 1 a 22020 0 222222
2 4I - 1 a 21212 2 222221
2 5I - 1 b02220 0 222221
2 6I - 1 a 20222 0 022222
2 7I - 1 b22222 0 222221
2 8I - 1 a 21220 0 022211
2 9I - 1 a 20020 0 222211
3 0I - 1 a 11020 0 012211
3 1I - 1 b12222 2 222221
3 2 I I - 1 11020 0 022211
ABCDE F GHI J KL
Number of studies 
with maximum 
score
1 2 7 1 32 3 62 1 72 53 13 12 21 0
Percentage of 
studies with 
maximum score (%)
38 22 41 72 19 6 53 78 97 97 69 31
Cochrane Bone, Joint and Muscle Trauma Group reporting quality assessment items:
A. Was the assigned treatment adequately concealed prior to allocation?
B. Were the outcomes of participants who withdrew described and included in the analysis (intention to treat)?
C. Were the outcome assessors blinded to treatment status?
D. Were the treatment and control group comparable at entry?
E. Were the participants blind to assignment status after allocation?
F. Were the treatment providers blind to assignment status?
G. Were care programs, other than the trial options, identical?
H. Were the inclusion and exclusion criteria clearly defined?
I. Were the interventions clearly defined?
J. Were the outcome measures used clearly defined?
K. Were diagnostic tests used in outcome assessment clinically useful?
L. Was the surveillance active, and of clinically appropriate duration?
[See Additional file 1].BMC Medical Research Methodology 2006, 6:44 http://www.biomedcentral.com/1471-2288/6/44
Page 7 of 8
(page number not for citation purposes)
describe aspects of critical appraisal separately and to
avoid summarizing results [18]. Our findings confirm the
variability of scores across each item of the Cochrane
reporting quality assessment tool.
Relevance of our findings
Despite the widely held belief that the Levels of Evidence
Rating system categorizes studies by quality [5,6], our
study suggests that this system, while reliable [7], may not
be a valid tool for determining the quality of a study, as
determined through the study reporting. As with any sys-
tem, whether it is the Levels of Evidence Rating or the
Cochrane reporting quality tool, the quality of study
reporting is critical. The CONSORT statement was devel-
oped to help authors improve the reporting quality of
RCTs [22]. In principle, this standardized scheme would
explicitly require reporting of all features critical to the
validity of a RCT and would require the presentation of
results in a standard manner to improve clarity [4]. Use of
the CONSORT statement is associated with improve-
ments in the reporting quality of RCTs [22]. However, the
reporting quality of RCTs in fracture care did not improve
following the introduction of the CONSORT statement
because many author's have not adopted the statement to
guide their reporting [3]. Our findings further identify a
lack of incorporation of the CONSORT statement in
orthopaedic trials; only four studies (13%) were ade-
quately reported with CONSORT guidelines. Journal edi-
torial boards and assessors must continue to enforce high
quality reporting of RCTs to allow an accurate assessment
of the level of evidence and other study reporting quality
measures.
Implications for future research
This study was underpowered to explore the influence of
reported statistical support, adherence to CONSORT
guidelines, multi-centre studies, and sources of funding
on the quality of reporting, direction of results, and mag-
nitude of treatment effect size. Future studies are needed
to explore any associations.
Conclusion
Our findings suggest that readers should not assume that
1) studies labelled as Level I have high quality of reporting
and 2) Level I studies have better reporting quality than
Level II studies. Methodological safeguards should be
addressed individually.
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Table 4: Mean and median Cochrane score for all items compared with Levels of Evidence
Cochrane score (max = 2 points for each A-L)
Level JBJS A B C D E F G H I J K L
% with score = 2 38% 22% 41% 72% 19% 6% 53% 78% 97% 97% 69% 31%
Mean Level I-1a 1.3 0.8 0.7 1.7 0.4 0.1 1.3 1.7 2.0 2.0 1.7 1.3
Median Level I-1a 1.0 1.0 0.0 2.0 0.0 0.0 1.5 2.0 2.0 2.0 2.0 1.0
Mean Level I-1b 1.0 1.0 1.7 1.4 0.6 0.3 1.4 1.9 2.0 2.0 1.7 1.1
Median Level I-1b 1.0 1.0 2.0 2.0 0.0 0.0 2.0 2.0 2.0 2.0 2.0 1.0
Mean Level II 1.0 0.7 0.0 0.7 0.0 0.0 0.7 2.0 2.0 1.7 1.7 1.3
Median level II 1.0 1.0 0.0 0.0 0.0 0.0 0.0 2.0 2.0 2.0 2.0 1.0
A N O V A  ( p  v a l u e ) * N SN SN SN SN SN SN SN SN SN SN SN S
Correlation (-) 0.04 0.2 0.1 0.2 0.1 0.2 0.0 0.3 0.1 0.2 0.03 0.1
p values corrected for post hoc comparisons (Bonferroni), NS = non-significant p value (P > 0.05)Publish with BioMed Central    and   every 
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